Literature DB >> 7671224

Breakpoint heterogeneity in t(10;11) translocation in AML-M4/M5 resulting in fusion of AF10 and MLL is resolved by fluorescent in situ hybridization analysis.

H B Beverloo1, M Le Coniat, J Wijsman, D M Lillington, O Bernard, A de Klein, E van Wering, J Welborn, B D Young, A Hagemeijer.   

Abstract

Ten AML-M4/M5 patients' samples containing a t(10;11) translocation, but with different cytogenetic breakpoints on chromosome 11q (11q13-23), were studied by G- and R-banding and fluorescent in situ hybridization. Southern blotting analysis, studied in five patients, revealed a rearranged MLL gene. Reverse transcription-PCR analysis carried out in six patients showed a 5' MLL-3' AF-10 fusion transcript. Fluorescent in situ hybridization studies suggested that in 8 of 10 patients, the rearrangement/fusion transcript resulted from an inversion of a part of 11q (q13q23) translocated to 10p12. In the other two patients, it is assumed that an inversion/translocation has occurred of a part of 10p to the der(11). The results suggest that the orientation of the AF-10 gene on 10p is 5' telomeric and 3' centromeric. This is the first example of opposite-oriented genes being involved in translocation to yield fusion transcripts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671224

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Widely expressed Af17 is likely not required for embryogenesis, hematopoiesis, and animal survival.

Authors:  Zhijing Zhang; Le Huang; Mary Rose Reisenauer; Hongyu Wu; Lihe Chen; Yujin Zhang; Yang Xia; Wenzheng Zhang
Journal:  Genesis       Date:  2010-11-17       Impact factor: 2.487

2.  The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family.

Authors:  M H Dreyling; J A Martinez-Climent; M Zheng; J Mao; J D Rowley; S K Bohlander
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

3.  Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.

Authors:  L Chen; A J Deshpande; D Banka; K M Bernt; S Dias; C Buske; E J Olhava; S R Daigle; V M Richon; R M Pollock; S A Armstrong
Journal:  Leukemia       Date:  2012-11-09       Impact factor: 11.528

4.  Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.

Authors:  Brian V Balgobind; Susana C Raimondi; Jochen Harbott; Martin Zimmermann; Todd A Alonzo; Anne Auvrignon; H Berna Beverloo; Myron Chang; Ursula Creutzig; Michael N Dworzak; Erik Forestier; Brenda Gibson; Henrik Hasle; Christine J Harrison; Nyla A Heerema; Gertjan J L Kaspers; Anna Leszl; Nathalia Litvinko; Luca Lo Nigro; Akira Morimoto; Christine Perot; Rob Pieters; Dirk Reinhardt; Jeffrey E Rubnitz; Franklin O Smith; Jan Stary; Irina Stasevich; Sabine Strehl; Takashi Taga; Daisuke Tomizawa; David Webb; Zuzana Zemanova; C Michel Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Blood       Date:  2009-06-15       Impact factor: 22.113

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.